With this in mind we used cell culture techniques and rodent models to examine, both in vitro and in vivo, the capacity of YC-1 as a HIF-1α inhibitor which might be used to control progestin-stimulated PR-dependent VEGF secretion and progression of progestin-dependent breast cancer. Here, PGR is linked to breast carcinoma.